Wed, Jul 23, 2014, 9:35 AM EDT - U.S. Markets close in 6 hrs 25 mins


% | $
Click the to save as a favorite.

Athenahealth, Inc. (ATHN) Message Board

goldpicks 3 posts  |  Last Activity: May 30, 2014 8:10 AM Member since: Nov 9, 1999
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • goldpicks by goldpicks May 30, 2014 8:10 AM Flag

    Alliqua's Tactics to Becoming a Significant Niche Player Follow Those of Horizon

    Alliqua, a growing name in wound care, seeks to build a portfolio of products that can take care of a wound from the initial diagnosis to final closure. As CEO David Johnson explained, the tactic is to expand its suite of technological solutions through acquisitions.

    Getting Off on the Right Foot

    In November 2013, Alliqua reached an agreement with Celgene (CELG) to develop and market the placenta-based wound healing product, Biovance. With the launch of Biovance in April, Alliqua penetrated one of the fastest-growing segments in the wound care market; placenta-based treatments.

    To complement the launch of Biovance, the company appointed the expansion of a dedicated sales force that will focus solely on Alliqua products. Strengthening brand awareness through an aggressive campaign will be critical for driving organic growth, a tactic that distinguished Horizon's Vimovo approach from AstraZeneca's.

    Alliqua also expects to obtain reimbursement under Medicare/Medicaid, which is expected to further assist in the adoption of Biovance. Due to the prolonged reimbursement procedure, accelerated ramp-up of Biovance is expected by year-end 2014.

    Funding Indicating Confidence and Progress of Strategy

    Prior to the Biovance launch, Alliqua raised $20.3 million in a series of transactions that included a $15.0 million private placement of common stock and warrants, and $5.3 million from the exercise of warrants from several institutional shareholders. The figures behind this funding suggested a vote of confidence from the involved parties.

    The strike price of the included warrants ($10.50/share) was at a 55% premium to market price, an encouraging sign denoting strong demand by long-term investors. Additionally, the $5.3 million raised from exercised warrants was a corporate action taken five years prior to expiration of the derivatives. The latest filing showed Celgene raised its stake in All

    Sentiment: Strong Buy

  • Reply to

    Sales Force has been fired

    by ken.londoner May 21, 2014 8:45 AM
    goldpicks goldpicks May 24, 2014 9:40 PM Flag

    There are only 4 sales positions posted. They fired at least 6 people on the East Coat alone

    Sentiment: Strong Sell

  • UnitedHealthcare, Aetna and Humana are leading efforts to make healthcare costs available for consumers to review online.
    The price transparency initiative, organized by the Health Care Cost Institute, will provide consumers with a reference price for episodes of care, such as knee replacements and heart surgery, in different communities based on aggregated data from the insurers, HCCI announced yesterday.
    "The public has been clamoring for this," HCCI Executive Director David Newman told Bloomberg. "This was the next natural step for us as an institute to evolve to."
    UnitedHealth, Aetna, Humana and Kaiser Permanente launched HCCI in 2011 and the nonprofit organization will create and operate the online pricing tool, which should be available early next year, based on cost information from the three participating insurers.
    Members of UnitedHealth, Aetna and Humana will have access to more specific pricing information, including out-of-pocket costs for certain services. And employers will be able to see even more "granular" information to customize health plans for their workers and create a seamless insurance experience regardless of payer.
    "We're looking to reorient the healthcare system around the consumer and we see this as another step in that process," Aetna spokesman Ethan Slavin told Bloomberg.
    Humana said the online tool will "satisfy consumer, employer and regulator demands for an easy and consistent way to compare prices by providing a free, single source of information on healthcare services, price and quality," Forbes reported.

    Sentiment: Sell

127.96+1.60(+1.27%)9:35 AMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.